Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

, KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

09:39
11/23/16
11/23
09:39
11/23/16
09:39

TheStreet's Feuerstein says 'highly likely' FDA shuts down Juno

TheStreet's Adam Feuerstein said via Twitter, "Seems highly likely, necessary, for FDA to shut down $JUNO entirely, all CAR-T programs, until they figure out what is going wrong." Along with Juno Therapeutics (JUNO), other companies developing CAR-T programs include Kite Pharma (KITE), ZIOPHARM (ZIOP) and bluebird bio (BLUE).

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

KITE

Kite Pharma

$51.69

-1.99 (-3.71%)

ZIOP

ZIOPHARM

$6.14

-0.27 (-4.21%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

  • 23

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.
11/03/16
BTIG
11/03/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
11/23/16
JANY
11/23/16
NO CHANGE
JANY
Weakness in bluebird bio unwarranted after Juno trial halt, says Janney Capital
KITE Kite Pharma
$51.69

-1.99 (-3.71%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
ZIOP ZIOPHARM
$6.14

-0.27 (-4.21%)

12/04/15
12/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affimed Therapeutics (AFMD) initiated with an Outperform at Wells Fargo... American Farmland (AFCO) initiated with an Outperform at Raymond James... Amgen (AMGN) initiated with a Market Perform at Wells Fargo... Applied Genetic (AGTC) initiated with an Outperform at Wells Fargo... BCE (BCE) initiated with a Buy at Goldman... Capital Product (CPLP) initiated with a Buy at Janney Capital... Celestica (CLS) initiated with a Neutral at B. Riley... Colfax (CFX) initiated with a Perform at Oppenheimer... Dimension Therapeutics (DMTX) initiated with an Outperform at Wells Fargo... Dover (DOV) initiated with a Perform at Oppenheimer... Fate Therapeutics (FATE) initiated with an Outperform at Wells Fargo... FibroGen (FGEN) initiated with a Buy at Citi... Finish Line (FINL) initiated with a Hold at BB&T... Five Prime (FPRX) resumed with an Outperform at Wells Fargo... Foot Locker (FL) initiated with a Buy at BB&T... GWG Holdings (GWGH) initiated with a Buy at Roth Capital... General Growth (GGP) initiated with an Outperform at Boenning & Scattergood... GigOptix (GIG) initiated with a Buy at Sterne Agee CRT... Halozyme (HALO) initiated with an Outperform at Wells Fargo... Hasbro (HAS) initiated with a Hold at Jefferies... Infinera (INFN) initiated with an Outperform at Raymond James... Inphi (IPHI) initiated with a Buy at Sterne Agee CRT... Inter Parfums (IPAR) initiated with an Overweight at KeyBanc... Intercept (ICPT) initiated with a Market Perform at Wells Fargo... Isis Pharmaceuticals (ISIS) initiated with an Outperform at Wells Fargo... LinkedIn (LNKD) initiated with a Buy at Nomura... Macerich (MAC) initiated with an Outperform at Boenning & Scattergood... Markit (MRKT) initiated with a Hold at Cantor... Mattel (MAT) initiated with a Buy at Jefferies... Maximus (MMS) initiated with a Buy at Stifel... MyoKardia (MYOK) initiated with an Outperform at Wells Fargo... Nimble Storage (NMBL) initiated with an Overweight at JPMorgan... OncoMed (OMED) initiated with an Outperform at Wells Fargo... Patriot National (PN) initiated with a Buy at Compass Point... Pennsylvania REIT (PEI) initiated with a Neutral at Boenning & Scattergood... Pixelworks (PXLW) initiated with a Buy at Craig-Hallum... Qualcomm (QCOM) initiated with an Overweight at Pacific Crest... Regeneron (REGN) initiated with an Outperform at Wells Fargo... Regulus (RGLS) initiated with an Outperform at Wells Fargo... Rogers Communications (RCI) initiated with a Neutral at Goldman... Rouse Properties (RSE) initiated with a Neutral at Boenning & Scattergood... Sangamo (SGMO) initiated with an Outperform at Wells Fargo... Sanmina (SANM) initiated with a Buy at B. Riley... Simon Property (SPG) initiated with an Outperform at Boenning & Scattergood... TELUS (TU) initiated with a Neutral at Goldman... TESARO (TSRO) initiated with an Outperform at Wells Fargo... Tokai Pharmaceuticals (TKAI) initiated with an Outperform at Wells Fargo... Vitae Pharmaceuticals (VTAE) initiated with an Outperform at Wells Fargo... ZIOPHARM (ZIOP) initiated with an Underperform at Wells Fargo... bluebird bio (BLUE) initiated with an Outperform at Wells Fargo.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
BMO Capital initiated bluebird bio with a Market Perform rating and $61 price target.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

INVH

Invitation Homes

$21.56

0.12 (0.56%)

15:06
06/23/17
06/23
15:06
06/23/17
15:06
Upgrade
Invitation Homes rating change  »

Invitation Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/23/17
06/23
15:05
06/23/17
15:05
General news
NY Fed's 3-day reverse repo totaled $201.5 B with 56 counterparties »

NY Fed's 3-day…

DAL

Delta Air Lines

$52.95

0.14 (0.27%)

15:03
06/23/17
06/23
15:03
06/23/17
15:03
Hot Stocks
Delta Air Lines, Korean Air create leading trans-Pacific joint venture »

Delta Air Lines and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

, XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

14:59
06/23/17
06/23
14:59
06/23/17
14:59
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX) at…

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

XLF

Financial Select Sector

$23.91

-0.07 (-0.29%)

XLE

Energy Select Sector SPDR

$64.16

0.21 (0.33%)

SPY

SPDR S&P 500 ETF Trust

$243.10

0.26 (0.11%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$62.64

0.918 (1.49%)

14:57
06/23/17
06/23
14:57
06/23/17
14:57
Periodicals
Breaking Periodicals news story on Tyson Foods »

Hedgeye names Tyson Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAA

Plains All American

$24.53

0.6301 (2.64%)

14:50
06/23/17
06/23
14:50
06/23/17
14:50
Options
Bullish long-term option play opened in Plains All American Pipeline »

Bullish long-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

LION

Fidelity Southern

$22.59

0.01 (0.04%)

14:46
06/23/17
06/23
14:46
06/23/17
14:46
Hot Stocks
Fidelity Southern announces appointment of Charles Christy as CFO »

Fidelity Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

14:40
06/23/17
06/23
14:40
06/23/17
14:40
General news
Fedspeak will resume with Chair Yellen »

Fedspeak will resume with…

14:30
06/23/17
06/23
14:30
06/23/17
14:30
Options
Alerian MLP attracts call buyers as shares attempt to rebound »

Alerian MLP attracts call…

LITE

Lumentum

$62.45

-0.05 (-0.08%)

14:25
06/23/17
06/23
14:25
06/23/17
14:25
Options
Lumentum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

14:20
06/23/17
06/23
14:20
06/23/17
14:20
General news
Action Economics Survey results »

Action Economics Survey…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

, SNE

Sony

$38.52

0.11 (0.29%)

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Periodicals
Nintendo market cap surpasses Sony's in Japan, Nikkei reports »

Nintendo's (NTDOY)…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

SNE

Sony

$38.52

0.11 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/23/17
06/23
14:16
06/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

14:15
06/23/17
06/23
14:15
06/23/17
14:15
Conference/Events
Portola Pharmaceuticals hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

SAFM

Sanderson Farms

$123.21

-2.89 (-2.29%)

14:08
06/23/17
06/23
14:08
06/23/17
14:08
Hot Stocks
Sanderson Farms to 'vigorously defend' California chicken lawsuit »

Sanderson Farms issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$60.50

3.847 (6.79%)

14:05
06/23/17
06/23
14:05
06/23/17
14:05
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
06/23/17
06/23
14:00
06/23/17
14:00
General news
Breaking General news story  »

Federal Reserve Board…

BLCM

Bellicum Pharmaceuticals

$13.98

1.33 (10.51%)

13:51
06/23/17
06/23
13:51
06/23/17
13:51
Recommendations
Bellicum Pharmaceuticals analyst commentary  »

Bellicum selloff after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

MDRX

Allscripts

$12.71

0.52 (4.27%)

13:50
06/23/17
06/23
13:50
06/23/17
13:50
Options
Second day of bullish option flow in Allscripts »

Second day of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$18.50

0.16 (0.87%)

13:45
06/23/17
06/23
13:45
06/23/17
13:45
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/23/17
06/23
13:40
06/23/17
13:40
General news
And now Fed's Mester warns that a failure to hike »

And now Fed's Mester…

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:36
06/23/17
06/23
13:36
06/23/17
13:36
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:35
06/23/17
06/23
13:35
06/23/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

GE

General Electric

$27.59

0.035 (0.13%)

13:30
06/23/17
06/23
13:30
06/23/17
13:30
Options
19.1K GE Jul - Aug 29 call spreads sold at 12c »

19.1K GE Jul - Aug 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.